Nachrichten zur DexCom Inc. Aktie

Key PointsRevenue (GAAP) rose 15% year-over-year in Q2 2025, easily surpassing expectations and driven by strong U.S. and international growth.Gross…

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended…

DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo…

Key PointsDexCom has barely scratched the surface of its niche in the diabetes market.As a result of industry challenges, the…

Key PointsThe Invesco QQQ Trust is focused on the best and most valuable growth stocks on the Nasdaq exchange.The Schwab…

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a…

Manchmal ist der beste Weg, einen Fehler zu beheben, darauf zu setzen. Genau das tut DexCom, der Hersteller von kontinuierlichen…

Die Entscheidung von DexCom, den Markt für Typ-2-Diabetes anzugehen, war nicht fehlerhaft. Das Problem lag in der Umsetzung der Strategie…

DexCom has significant room to grow in its core market, despite disappointing results last year. One of Warren Buffetts…

Geschäftstreiber:Dexcom (DGX) Das Unternehmen gilt als Anbieter der branchenweit fortschrittlichsten kontinuierlichen Blutzuckermesssensoren (CGMs), die Diabetiker beim Insulinmanagement unterstützten.... …

Dexcom Deutschland GmbH: Mainz (ots) - - Das einfach zu bedienende [1] Dexcom G7 lässt sich jetzt mit Omnipod 5,…

Over the past few years, Medtronic (NYSE: MDT) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth,…

Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy…

Investors typically want to beat the market over the long run. Though its not an easy task, it certainly is…

DexCom shares surge as Q1 revenue beats expectations…

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has…

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its…

In this podcast, Motley Fool analysts talk about economic uncertainty, airlines, building materials, and assorted spirits. Motley Fool analyst Asit Sharma…

With equity markets reeling due to President Donald Trumps tariffs, many investors are taking this opportunity to buy shares of…

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding…

What should investors do during a market downturn? Some might resort to panic selling, but thats hardly a good strategy.…

DexCom shares rise on FDA clearance for new CGM system…

DexComs recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.…

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The…

Equity markets started 2025 pretty well, but things havent been so rosy in the past couple of months. The tech-heavy…

Novo Nordisks weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom…

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections…

Dexcom receives FDA warning letter for two U.S. manufacturing facilities…

The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth…

AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.…

DXCM earnings call for the period ending December 31, 2024.…

DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short.…

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but…

DexCom (DXCM) delivered earnings and revenue surprises of -10% and 0.05%, respectively, for the quarter ended December 2024. Do the…

Most companies dont survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull…

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo…

DexCom (DXCM) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. However,…

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors…

The bull market of the past year or more has reinvigorated investors interest across a range of industries, and the…

Tony Zhang gives an update on his successful Dexcom trade.…

DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if…

…

Stocks tend to perform well in January, but thats not a good reason to invest this month. Strong returns arent…

Dexcom stock soars on upbeat 2025 revenue outlook…

The past year was a great one for the stock market as a whole, but there were plenty of companies…

Now that weve shut the door on 2024, its useful to look back at some of the best -- and,…

…

DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend…

Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors…